louisiana semaglutide intestinal paralysis class action bowel obstruction lawsuit in Semaglutide Lawsuit Filed Against Ozempic & Wegovy Makers Ozempic Stomach Paralysis Lawsuit [2026

In some cases, switching to a different GLP-1 receptor agonist or alternative diabetes or weight management therapy may be recommended

In clinical studies, adults taking the currently FDA-approved doses of Rybelsus for type 2 diabetes (3 mg, 7 mg, and 14 mg daily) lost an average of about 35% of their body weight

GLP-1 (glucagon-like peptide-1) receptor agonists, such as semaglutide and liraglutide, were originally developed to treat type 2 diabetes but have also shown strong effectiveness in managing obesity and supporting weight loss

If corticosteroids are used, basal insulin may not be sufficient

For management strategies, see our semaglutide side effects guide